Literature DB >> 23022638

Effective surgical revascularization improves cerebral hemodynamics and resolves headache in pediatric Moyamoya disease.

Masahito Kawabori1, Satoshi Kuroda, Naoki Nakayama, Kenji Hirata, Toru Shiga, Kiyohiro Houkin, Nagara Tamaki.   

Abstract

BACKGROUND: Headache is one of the major clinical presentations in pediatric Moyamoya disease. However, the clinical features and underlying mechanisms are not fully understood. This study aimed to clarify the clinical feature of headache in pediatric Moyamoya disease and the effect of surgical revascularization.
METHODS: This study included 29 pediatric patients who underwent superficial temporal artery to middle cerebral artery (STA-MCA) anastomosis and indirect bypass for Moyamoya disease. Their medical records were precisely evaluated to identify the clinical features of their headache. The findings on magnetic resonance imaging, positron emission tomography, and single-photon emission computed tomography also were analyzed.
RESULTS: Preoperative headache was documented in 11 (38%) of 29 patients. The majority of them complained of severe headache in the frontal or temporal region in the morning. Headache was significantly related to more advanced disease stage and to the decreases in cerebral blood flow and its reactivity to acetazolamide. Surgical revascularization completely resolved headache in all 11 patients.
CONCLUSIONS: These findings strongly suggest that disturbed cerebral hemodynamics may play key roles in developing severe headache in pediatric Moyamoya disease. STA-MCA anastomosis and encephalo-duro-myo-arterio-pericranial synangiosis may be effective procedures to rapidly resolve headache by widely supplying collateral blood flow to the operated hemispheres.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ACZ; Acetazolamide; Bypass surgery; CBF; CVR; Cerebral blood flow; Cerebral hemodynamics; Cerebrovascular reactivity; EDAS; EDMAPS; Encephalo-duro-arterio-synangiosis; Encephalo-duro-myo-arterio-pericranial synangiosis; Headache; MR; Magnetic resonance; Moyamoya disease; PET; Positron emission tomography; SPECT; STA-MCA; Single-photon emission computed tomography; Superficial temporal artery to middle cerebral artery; TIA; Transient ischemic attack

Mesh:

Year:  2012        PMID: 23022638     DOI: 10.1016/j.wneu.2012.08.005

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  6 in total

1.  Headache attack followed by rapid disease progression in pediatric moyamoya disease--how should we manage it?

Authors:  Sandra Vuignier; Naoki Akioka; Hideo Hamada; Daina Kashiwazaki; Satoshi Kuroda
Journal:  Childs Nerv Syst       Date:  2014-04-01       Impact factor: 1.475

2.  Early surgical treatment benefits early staged pediatric moyamoya disease--single case report.

Authors:  Go Matsuoka; Yasuo Aihara; Koji Yamaguchi; Tatsuya Ishikawa; Akitsugu Kawashima; Takakazu Kawamata; Yoshikazu Okada
Journal:  Childs Nerv Syst       Date:  2015-04-23       Impact factor: 1.475

Review 3.  Neuroimaging of vascular reserve in patients with cerebrovascular diseases.

Authors:  Meher R Juttukonda; Manus J Donahue
Journal:  Neuroimage       Date:  2017-10-12       Impact factor: 6.556

Review 4.  Recent advances in moyamoya disease: pathophysiology and treatment.

Authors:  Annick Kronenburg; Kees P J Braun; Albert van der Zwan; Catharina J M Klijn
Journal:  Curr Neurol Neurosci Rep       Date:  2014-01       Impact factor: 5.081

5.  Clinical Characteristics and Long-Term Outcome of Headaches Associated With Moyamoya Disease in the Chinese Population-A Cohort Study.

Authors:  Bin Gao; Kaijiang Kang; Jia Zhang; Dong Zhang; Xingquan Zhao
Journal:  Front Neurol       Date:  2020-11-26       Impact factor: 4.003

Review 6.  Pathophysiology of Vascular Stenosis and Remodeling in Moyamoya Disease.

Authors:  Brandon M Fox; Kirsten B Dorschel; Michael T Lawton; John E Wanebo
Journal:  Front Neurol       Date:  2021-09-03       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.